compound introduction
CUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers. In Vitro GDC-0917 (0.1 nM-10 μM) induces reduction of cIAP1 levels in PBMCs in a concentration-dependent manner showing greater than 80% inhibition at concentrations greater than 0.1 µM (56.5 ng/mL). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo GDC-0917 (0.08-16.3 mg/kg) exhibits antitumor activity in a dose dependent manner in the MDA-MB-231-X1.1 Breast Cancer Xenograft, and GDC-0917 is well tolerated, with all dose groups experiencing a Form:Solid
